Status:
UNKNOWN
Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19
Lead Sponsor:
Astana Medical University
Conditions:
Respiratory Distress Syndrome
Hypoxemia
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Vibroacoustic pulmonary therapy in patients with COVID19 is believed to have a positive effect on oxygen status and a decrease in the duration of respiratory failure
Detailed Description
This study aims to recruit the required number of patients for statistical identification of the effectiveness of vibroacoustic therapy in patients with COVID 19. Obligatory performance criteria will ...
Eligibility Criteria
Inclusion
- adults
- P/F less 300 torr
- ARDS by Berlin convention
- COVID 19 bilateral pneumonia
Exclusion
- children
- acute brain stroke
- acute coronary syndrome
- pulmonary embolism
- implanted pacemaker
Key Trial Info
Start Date :
March 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04435353
Start Date
March 22 2020
End Date
February 1 2021
Last Update
June 17 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mukatova Irina
Astana, Astana, Kazakhstan, 010000
2
Center of pulmonology Astana
Astana, Kazakhstan, 010000